Hepatitis B Diagnosis

Hepatitis B is a viral infection that enters liver cells and can trigger inflammation. Acute infection may resolve, while chronic infection can persist and gradually cause fibrosis, cirrhosis, liver failure, or liver cancer.

Many people have no early symptoms. When symptoms occur, they may include fatigue, poor appetite, nausea, vomiting, right-upper abdominal discomfort, fever, dark urine, pale stool, joint pain, or jaundice.

Hepatitis B spreads through infected blood and certain body fluids, including through sex, shared needles or injection equipment, unsafe blood exposure, and from an infected mother to a baby during birth.

Yes. Infection that persists becomes chronic hepatitis B. The chance of chronic infection is much higher when infection occurs during infancy or early childhood than when it occurs in a healthy adult.

Initial screening commonly uses HBsAg, anti-HBs, and total anti-HBc. Additional tests such as IgM anti-HBc, HBV DNA, HBeAg, liver enzymes, and repeat results help determine whether infection is acute or chronic and how active it is.

Acute hepatitis B is a recent infection. Chronic hepatitis B persists over time and requires ongoing liver monitoring. Symptoms alone cannot reliably distinguish them; marker patterns and the duration of positive results are important.

Current treatment can strongly suppress chronic hepatitis B and reduce liver complications, but it does not reliably eliminate the virus from every infected liver cell. A functional cure can occur in some patients but is not the usual treatment outcome.

Several licensed hepatitis B vaccine schedules are available for infants, children, and adults. The appropriate product and number of doses depend on age, health status, and prior vaccination. A clinician can confirm the recommended schedule.

Yes. Long-term infection can lead to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Risk varies, which is why some patients need antiviral therapy and regular liver-cancer surveillance even when they feel well.

Preferred oral antiviral medicines can suppress HBV replication. Treatment selection and duration depend on viral load, ALT, fibrosis or cirrhosis, pregnancy, kidney health, prior treatment, coinfections, and other clinical factors.

Hepatitis B is not spread through hugging, coughing, sneezing, sharing a room, or ordinary social contact. Saliva alone is not a common route, although blood-contaminated personal items such as razors or toothbrushes should not be shared.

Acute infection may clear within months, while chronic infection can last for life. Follow-up blood tests determine whether surface antigen disappears or persists and whether long-term monitoring is required.

Do not share needles, razors, toothbrushes, or items contaminated with blood. Cover open cuts, practice safer sex until partners are confirmed immune, tell medical professionals about the infection, and encourage susceptible close contacts to be vaccinated.

Pregnancy does not automatically worsen hepatitis B, but a high viral load can increase transmission risk during birth. Pregnant patients need HBsAg screening, timely viral-load assessment when positive, and coordinated newborn vaccine and immune-globulin protection.

HBV DNA viral load measures the amount of hepatitis B genetic material in the blood. It helps show viral replication and is interpreted with ALT, fibrosis, cirrhosis, pregnancy, age, and other factors when deciding treatment and monitoring.

No. Some patients need monitoring without immediate medication, while others benefit from antiviral therapy. Treatment decisions consider HBV DNA, liver enzymes, fibrosis or cirrhosis, pregnancy, immune suppression, coinfections, and liver-cancer risk.